Across TCGA pan-cancer cohorts, ADH7 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ADH7 data layer compared with 19 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADH7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADH7 expression acts as an unfavorable survival marker.
LUAD are the cancer types where ADH7 mass-spec protein most reproducibly stratifies survival.